Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis

OBJECTIVES: To determine whether patients with early rheumatoid arthritis (ERA) have cardiovascular disease (CVD) that is modifiable with disease-modifying antirheumatic drug (DMARD) therapy, comparing first-line etanercept (ETN) + methotrexate (MTX) with MTX strategy. METHODS: Patients from a phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Plein, Sven, Erhayiem, Bara, Fent, Graham, Horton, Sarah, Dumitru, Raluca Bianca, Andrews, Jacqueline, Greenwood, John P, Emery, Paul, Hensor, Elizabeth MA, Baxter, Paul, Pavitt, Sue, Buch, Maya H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569379/
https://www.ncbi.nlm.nih.gov/pubmed/32859608
http://dx.doi.org/10.1136/annrheumdis-2020-217653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569379/
https://www.ncbi.nlm.nih.gov/pubmed/32859608
http://dx.doi.org/10.1136/annrheumdis-2020-217653

Ejemplares similares